How old is this mutation? - a study of three Ashkenazi Jewish founder mutations

Greenwood, Celia M. T; Shuying Sun; Veenstra, Justin; Hamel, Nancy; Niell, Bethany; Gruber, Stephen; Foulkes, William D.
January 2010
BMC Genetics;2010, Vol. 11, p39
Academic Journal
Background: Several founder mutations leading to increased risk of cancer among Ashkenazi Jewish individuals have been identified, and some estimates of the age of the mutations have been published. A variety of different methods have been used previously to estimate the age of the mutations. Here three datasets containing genotype information near known founder mutations are reanalyzed in order to compare three approaches for estimating the age of a mutation. The methods are: (a) the single marker method used by Risch et al., (1995); (b) the intra-allelic coalescent model known as DMLE, and (c) the Goldgar method proposed in Neuhausen et al. (1996), and modified slightly by our group. The three mutations analyzed were MSH2*1906 G->C, APC*I1307K, and BRCA2*6174delT. Results: All methods depend on accurate estimates of inter-marker recombination rates. The modified Goldgar method allows for marker mutation as well as recombination, but requires prior estimates of the possible haplotypes carrying the mutation for each individual. It does not incorporate population growth rates. The DMLE method simultaneously estimates the haplotypes with the mutation age, and builds in the population growth rate. The single marker estimates, however, are more sensitive to the recombination rates and are unstable. Mutation age estimates based on DMLE are 16.8 generations for MSH2 (95% credible interval (13, 23)), 106 generations for I1037K (86-129), and 90 generations for 6174delT (71-114). Conclusions: For recent founder mutations where marker mutations are unlikely to have occurred, both DMLE and the Goldgar method can give good results. Caution is necessary for older mutations, especially if the effective population size may have remained small for a long period of time.


Related Articles

  • Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. Hamel, Nancy; Kotar, Kimberley; Foulkes, William D. // BMC Medical Genetics;2003, Vol. 4, p1 

    Background: Relatives of BRCA1 and BRCA2 mutation carriers have long been proposed by epidemiological studies to have an increased risk of developing prostate cancer. In the Ashkenazi Jewish (AJ) population, the existence of 3 frequent founder mutations, 185delAG and 5382insC in BRCA1 and...

  • Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation. Rinella, Erica; Shao, Yongzhao; Yackowski, Lauren; Pramanik, Sreemanta; Oratz, Ruth; Schnabel, Freya; Guha, Saurav; LeDuc, Charles; Campbell, Christopher; Klugman, Susan; Terry, Mary; Senie, Ruby; Andrulis, Irene; Daly, Mary; John, Esther; Roses, Daniel; Chung, Wendy; Ostrer, Harry // Human Genetics;May2013, Vol. 132 Issue 5, p523 

    The ability to establish genetic risk models is critical for early identification and optimal treatment of breast cancer. For such a model to gain clinical utility, more variants must be identified beyond those discovered in previous genome-wide association studies (GWAS). This is especially...

  • Inferring Population Parameters From Single-Feature Polymorphism Data. Rong Jiang; Marjoram, Paul; Borevitz, Justin O.; Tavaré, Simon // Genetics;Aug2006, Vol. 173 Issue 4, p2257 

    This article is concerned with a statistical modeling procedure to call single-feature polymorphisms from microarray experiments. We use this new type of polymorphism data to estimate the mutation and recombination parameters in a population. The mutation parameter can be estimated via the...

  • The Anomalous Effects of Biased Mutation Revisited: Mean-Optimum Deviation and Apparent Directional Selection Under Stabilizing Selection. Xu-Sheng Zhang; Hill, William G. // Genetics;Jun2008, Vol. 179 Issue 2, p1135 

    Empirical evidence indicates that the distribution of the effects of mutations on quantitative traits is not symmetric about zero. Under stabilizing selection in infinite populations with normally distributed mutant effects having a nonzero mean, Waxman and Peck showed that the deviation of the...

  • On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Hamel, Nancy; Feng, Bing-Jian; Foretova, Lenka; Stoppa-Lyonnet, Dominique; Narod, Steven A; Imyanitov, Evgeny; Sinilnikova, Olga; Tihomirova, Laima; Lubinski, Jan; Gronwald, Jacek; Gorski, Bohdan; Hansen, Thomas v O; Nielsen, Finn C; Thomassen, Mads; Yannoukakos, Drakoulis; Konstantopoulou, Irene; Zajac, Vladimir; Ciernikova, Sona; Couch, Fergus J; Greenwood, Celia M T // European Journal of Human Genetics;Mar2011, Vol. 19 Issue 3, p300 

    The BRCA1 mutation c.5266dupC was originally described as a founder mutation in the Ashkenazi Jewish (AJ) population. However, this mutation is also present at appreciable frequency in several European countries, which raises intriguing questions about the origins of the mutation. We genotyped...

  • Influences of Dominance and Evolution of Sex in Finite Diploid Populations. Chang, Yujun; Hua, Yuan; Jiang, Xiaoqian; Tao, Shiheng // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Most eukaryotes reproduce sexually. Although the benefits of sex in diploids mainly stem from recombination and segregation, the relative effects of recombination and segregation are relatively less known. In this study, we adopt an infinite loci model to illustrate how dominance coefficient of...

  • Selection dramatically reduces effective population size in HIV-1 infection. Yi Liu; Mittler, John E. // BMC Evolutionary Biology;2008, Vol. 8, Special section p1 

    Background: In HIV-1 evolution, a 100-100,000 fold discrepancy between census size and effective population size (Ne) has been noted. Although it is well known that selection can reduce Ne, high in vivo mutation and recombination rates complicate attempts to quantify the effects of selection on...

  • RESPONSE. Zecevic, Maja; Amos, Christopher I.; Frazier, Marsha L. // JNCI: Journal of the National Cancer Institute;11/15/2006, Vol. 98 Issue 22, p1665 

    The article comments on a report about the study of genetic polymorphism and risk factors in colorectal cancer. A statistical study suggests that there is a significant connection between the IGF-1 CA-repeat lengths and the increased age-associated risk for hereditary nonpolyposis colorectal...

  • Genomic technology: Recombination maps get personal. Burgess, Darren J. // Nature Reviews Genetics;Sep2012, Vol. 13 Issue 9, p597 

    The article discusses research which used a single-cell augmentation approach for the generation on recombination maps, which references the study "Genome-wide single-cell analysis of recombination activity and de novo mutation rates in human sperm," by J. Wang and colleagues in the 2012 issue.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics